Thalidomide: A new beginning

Cancer Practice

Volumn 8, Issue 2, 2000, Pages 101-103

  Valorie, Anne Marie ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

CACHEXIA; CANCER; DOSE CALCULATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; GRAFT VERSUS HOST REACTION; MULTIPLE MYELOMA; PRESCRIPTION; PROPHYLAXIS; SHORT SURVEY; TERATOGENICITY;

ANGIOGENESIS INHIBITORS; CACHEXIA; FORECASTING; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; NEOPLASMS; PRESCRIPTIONS, DRUG; THALIDOMIDE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0034007581     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5394.2000.82009.x     Document Type: Short Survey

References (16)

1. Miller JL. Thalidomide recommended for approval under tight restrictions. Am J Health-Sys Pharmacists. 1997;54:2270-2280.
2. Thalomid [package insert]. Warren, NJ: Celgene; 1998.
3. Folkman J. Angiogenesis: mechanistic insights, neovascular diseases in cancer, rheumatoid, and other disease. Nat Med. 1995;1:27-31.
4. O'Reilly MS. The preclinical evaluation of angiogenesis inhibitors. Invest New Drugs. 1997;15(1):5-13.
5. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft versus host disease. N Engl J Med. 1992;326:1055-1058.
6. Singhal S, Mehta J, Eddlemon P, et al. Marked anti-tumor effect from anti-angiogenesis therapy with thalidomide in high-risk refractory multiple myeloma [abstract]. Blood. 1998;92(suppl 1):318a.
7. Barlogie B, Desikan N, Munshi D, et al. Single Course D.T. PACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma [abstract]. Blood. 1998;92(suppl 1):273b.
8. Watanabe S, Pituskin E, Calder K, et al. Thalidomide in the symptomatic treatment of cachexia in patients with terminal cancer [abstract]. Proc Am Soc Clin Oncol Annu Meet. 1999. Abstract 180.
9. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS. 1996;10:1501-1507.
10. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft versus host disease. Blood. 1995;86:3604-3609.
11. Rovelli A, Arringo C, Nesi F, et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant. 1998;21:577-581.
12. Figg WD, Bergan R, Brawley O, et al. Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC) [abstract]. Proc Am Soc Clin Oncol Annu Meet. 1997; 16:1189.
13. Eisen T, Boshoff C, Pyle MM, et al. Anti-angiogenic treatment of metastatic melanoma, renal call carcinoma, ovarian and breast cancers with thalidomide: a phase II study [abstract]. Proc Am Soc Clin Oncol Annu Meet. 1998;17:441a. Abstract 1699.
14. Fine HA, Loeffler JS, Kyritis A, et al. A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas [abstract]. Proc Am Soc Clin Oncol Annu Meet. 1997;16:A1372. Abstract 1372.
15. Marx GM, Levi JA, Bell DR, et al. A phase I/II trial of thalidomide as an antiangiogenic agent in the treatment of advanced cancer [abstract]. Proc Am Soc Clin Oncol Annu Meet. 1999;18. Abstract 1751.
16. Corral L, Haslett P, Muller G, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380-386.